Skip to content
Trending storyDeveloping

AMA and EMA issue joint guidance for Bundibugyo Ebola vaccine development

1 report1 sourceupdated 3 hours ago

Start here

Synthesis

The AMA and EMA have released a joint position paper on advancing candidate vaccines against Ebola disease caused by Bundibugyo virus (BDBV). The guidance aims to move candidates through clinical trial phases as quickly as possible while maintaining rigorous scientific evaluation and protecting trial participants. It sets minimum requirements for starting clinical trials and recommends a single-dose vaccine, non-human challenge studies, and a Phase III ring trial based on randomised inclusion of close contacts of confirmed cases. For candidates with sufficient platform data, postponing or waiving certain animal toxicity studies can be scientifically justified. Trials in children and pregnant women should begin once adequate initial adult safety data are available.

Written by a model from the reports · updated 3 hours ago

Coverage timeline

Follow the coverage to see the different angles.

Oct 23
  1. ema.europa.euPick
    AMA and EMA issue joint guidance on Ebola vaccine development

    The African Medicines Agency and EMA have issued a joint position paper supporting faster movement of candidate vaccines against Bundibugyo virus (BDBV) Ebola disease through clinical trial phases while maintaining rigorous scientific evaluation and participant safeguards. The paper sets minimum requirements to start clinical trials and recommends a single-dose vaccine, non-human challenge studies, and a Phase III ring trial based on randomised inclusion of close contacts of confirmed cases. For candidates with well-characterised platform data, postponing or waiving certain animal toxicity studies can be scientifically justified; trials in children and pregnant women should begin once sufficient initial adult safety data are available.

Heat trend for this story

Heat now 9·Peak in the comparable set 10 (Oct 23 18:00)·Change over 24h in the comparable set –·Participants now 1

Participants counted1
00.250.50.751
Heat over time
02.557.510Oct23Oct23Oct23Oct23

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org